Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.
Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention?
A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1. This has made many tumors amenable to immunotherapy. However, the generalized nature of the responses induced includes some serious side effects such as autoimmune disease.
Q. What are the new opportunities emerging in your field of work?
A. A major opportunity is to figure out how to combine immunotherapies, and also how to target immunotherapy to the tumor and avoid some of the autoimmune side effects.
Q. What are the key take away points from your presentation topic which will help in building the knowledge base of attendees?
A. The main take away should be that it is feasible to develop targeted immune responses to cancer when one understands how the immune system functions with specific antigen recognition in the context of HLA molecules. These insights should lead to targeted immunotherapies that are both personalized and off-the-shelf.
Q. Hope you had a chance to go through the agenda, what are your views on it and how helpful it is to the targeted audience
A. I think the agenda is good and will be quite helpful to the target audience.
William Williams will present on Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors.
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2LNkgpQ
For more inquiries contact Amit Shelke, Marketing Manager on firstname.lastname@example.org